MYO-029 is an antibody (immune-system protein) designed to stick to and interfere with the actions of myostatin, a protein that limits muscle growth.
Beginning in 2005 Wyeth began a phase 1-2 clinical trial to test the safety and tolerability of MYO-029 in 116 adults
However, the investigators found no improvements in muscle strength or function, and no statistically significant muscle growth in trial participants. Development of MYO-029 was discontinued 2008.